New market launch: TIEFENBACHER PHARMACEUTICALS successfully launches first generic version of the Multiple Sclerosis (MS) medicine Teriflunomide in Canda
We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why Tiefenbacher Pharmaceuticals is happy to share that we have successfully prepared the launch of the generic version of Teriflunomide for a market entry on day one after patent expiration in Canada.
Teriflunomide is used to improve the life of patients suffering from Multiple Sclerosis (MS) – a chronic disease that effects the central nervous system. The 14 mg film coated tablets are developed and produced in TIEFENBACHER GROUPs own site in India and will be marketed in Canada by our partners, two well-known generic pharmaceutical companies. Our product has already been launched in time in Australia before – a launch in further international markets will follow as soon as the patents of the originator product expire. With this generic market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
